268 related articles for article (PubMed ID: 17515401)
1. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene.
Goel A; Carlson SK; Classic KL; Greiner S; Naik S; Power AT; Bell JC; Russell SJ
Blood; 2007 Oct; 110(7):2342-50. PubMed ID: 17515401
[TBL] [Abstract][Full Text] [Related]
2. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.
Dingli D; Peng KW; Harvey ME; Greipp PR; O'Connor MK; Cattaneo R; Morris JC; Russell SJ
Blood; 2004 Mar; 103(5):1641-6. PubMed ID: 14604966
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.
Velazquez-Salinas L; Naik S; Pauszek SJ; Peng KW; Russell SJ; Rodriguez LL
Hum Gene Ther Clin Dev; 2017 Jun; 28(2):108-115. PubMed ID: 28514874
[TBL] [Abstract][Full Text] [Related]
5. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW
Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908
[TBL] [Abstract][Full Text] [Related]
6. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
Naik S; Nace R; Barber GN; Russell SJ
Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus.
Alkayyal AA; Ajina R; Cacciabue M; Alkayyal AA; Saeedi NH; Hussain Alshehry T; Kaboha F; Alotaibi MA; Zaidan N; Shah K; Alroqi F; Bakur Mahmoud A
Front Immunol; 2023; 14():1082191. PubMed ID: 36798114
[TBL] [Abstract][Full Text] [Related]
8. Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.
Zhang L; Steele MB; Jenks N; Grell J; Suksanpaisan L; Naik S; Federspiel MJ; Lacy MQ; Russell SJ; Peng KW
Hum Gene Ther Clin Dev; 2016 Sep; 27(3):111-22. PubMed ID: 27532609
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy.
Li H; Peng KW; Russell SJ
Hum Gene Ther; 2012 Mar; 23(3):295-301. PubMed ID: 22235810
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.
Yarde DN; Nace RA; Russell SJ
Exp Hematol; 2013 Dec; 41(12):1038-49. PubMed ID: 24067362
[TBL] [Abstract][Full Text] [Related]
11. HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy.
Li H; Nakashima H; Decklever TD; Nace RA; Russell SJ
Cancer Gene Ther; 2013 Aug; 20(8):478-85. PubMed ID: 23868101
[TBL] [Abstract][Full Text] [Related]
12. Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS).
Opyrchal M; Allen C; Iankov I; Aderca I; Schroeder M; Sarkaria J; Galanis E
Hum Gene Ther; 2012 Apr; 23(4):419-27. PubMed ID: 22185260
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors.
Dwyer RM; Bergert ER; O'Connor MK; Gendler SJ; Morris JC
Hum Gene Ther; 2006 Jun; 17(6):661-8. PubMed ID: 16776574
[TBL] [Abstract][Full Text] [Related]
14. Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene.
Grünwald GK; Vetter A; Klutz K; Willhauck MJ; Schwenk N; Senekowitsch-Schmidtke R; Schwaiger M; Zach C; Wagner E; Göke B; Holm PS; Ogris M; Spitzweg C
J Nucl Med; 2013 Aug; 54(8):1450-7. PubMed ID: 23843567
[TBL] [Abstract][Full Text] [Related]
15. Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer.
Penheiter AR; Wegman TR; Classic KL; Dingli D; Bender CE; Russell SJ; Carlson SK
AJR Am J Roentgenol; 2010 Aug; 195(2):341-9. PubMed ID: 20651188
[TBL] [Abstract][Full Text] [Related]
16. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.
Msaouel P; Iankov ID; Allen C; Aderca I; Federspiel MJ; Tindall DJ; Morris JC; Koutsilieris M; Russell SJ; Galanis E
Mol Ther; 2009 Dec; 17(12):2041-8. PubMed ID: 19773744
[TBL] [Abstract][Full Text] [Related]
18. Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses.
Miller A; Nace R; Ayala-Breton C C; Steele M; Bailey K; Peng KW; Russell SJ
Mol Ther; 2016 Feb; 24(2):306-317. PubMed ID: 26647825
[TBL] [Abstract][Full Text] [Related]
19. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.
Mansfield DC; Kyula JN; Rosenfelder N; Chao-Chu J; Kramer-Marek G; Khan AA; Roulstone V; McLaughlin M; Melcher AA; Vile RG; Pandha HS; Khoo V; Harrington KJ
Gene Ther; 2016 Apr; 23(4):357-68. PubMed ID: 26814609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
